IRIS
PINATO, David James
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.372
NA - Nord America 1.548
AS - Asia 1.001
Continente sconosciuto - Info sul continente non disponibili 3
AF - Africa 2
SA - Sud America 1
Totale 4.927
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.535
IE - Irlanda 1.234
HK - Hong Kong 501
SG - Singapore 354
SE - Svezia 332
IT - Italia 277
UA - Ucraina 169
DE - Germania 139
FR - Francia 89
CN - Cina 63
FI - Finlandia 58
IN - India 31
IR - Iran 28
NL - Olanda 16
GB - Regno Unito 14
CA - Canada 13
CZ - Repubblica Ceca 12
BE - Belgio 8
JP - Giappone 8
VN - Vietnam 8
AT - Austria 5
CH - Svizzera 5
RU - Federazione Russa 5
PL - Polonia 4
EU - Europa 3
BF - Burkina Faso 2
LI - Liechtenstein 2
LT - Lituania 2
PK - Pakistan 2
AM - Armenia 1
CO - Colombia 1
CY - Cipro 1
KR - Corea 1
MY - Malesia 1
PT - Portogallo 1
TR - Turchia 1
TW - Taiwan 1
Totale 4.927
Salva come PNG Salva come JPEG
Città #
Dublin 1.231
Hong Kong 501
Singapore 251
Lawrence 149
Princeton 149
Jacksonville 139
Wilmington 138
San Mateo 125
Chandler 113
Dearborn 55
Piemonte 46
Ann Arbor 38
Ashburn 38
Helsinki 31
Boardman 27
Novara 27
Andover 23
Vercelli 23
Strasbourg 22
Beijing 20
Turin 19
Bremen 18
Santa Clara 18
Milan 16
Zanjan 16
Norwalk 14
Amsterdam 12
Pleasantville 12
Woodbridge 11
Houston 10
West Jordan 10
Brussels 8
Dong Ket 8
Los Angeles 8
Munich 8
Toronto 8
Brno 7
Frankfurt am Main 7
Nanjing 7
Mezzomerico 6
Hangzhou 5
Hefei 5
Kunming 5
New York 5
Zurich 5
Cassano Magnago 4
Kitakyushu 4
London 4
Vienna 4
Düsseldorf 3
Fairfield 3
Kraków 3
Leipzig 3
Minamiyukigaya 3
Nuremberg 3
Pardubice 3
Rome 3
Sacramento 3
Schwabmünchen 3
Augusta 2
Bologna 2
Borgomanero 2
Cambridge 2
Chicago 2
Deiva Marina 2
Delhi 2
Des Moines 2
Dreieich 2
Fort Worth 2
Genoa 2
Grafing 2
Jinan 2
Leawood 2
Legnano 2
Magnago 2
Meppel 2
Moncalieri 2
Monmouth Junction 2
Mumbai 2
Nanchang 2
New Delhi 2
Odalengo Grande 2
Ottawa 2
Philadelphia 2
Prague 2
Redwood City 2
Ryazan 2
Seattle 2
Verona 2
Villasanta 2
Ardabil 1
Asahikawa 1
Baotou 1
Berlin 1
Biella 1
Brixton 1
Casoria 1
Changchun 1
Duncan 1
Espoo 1
Totale 3.512
Salva come PNG Salva come JPEG
Nome #
Validation of the Hepatoma Arterial Embolization Prognostic Score in European and Asian Populations and Proposed Modification. 94
Evaluation of the red cell distribution width as a biomarker of early mortality in hepatocellular carcinoma 70
On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study 67
Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib 67
Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: A multi-center comparative study 67
Long-term sequelae are highly prevalent one year after hospitalization for severe COVID-19 67
The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma 62
Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma 62
The albumin–bilirubin grade improves hepatic reserve estimation post-sorafenib failure: implications for drug development 56
Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study 56
Presenting features and early mortality from SARS-CoV-2 infection in cancer patients during the initial stage of the COVID-19 pandemic in Europe 56
HBV AND LYMPHOMAGENESIS: NOVEL INSIGHTS INTO AN OCCULT RELATIONSHIP 54
Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study 52
Prognostic sub-classification of intermediate-stage hepatocellular carcinoma: a multicenter cohort study with propensity score analysis. 51
Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients 50
Prevalence and impact of COVID-19 sequelae on treatment pathways and survival of patients with cancer who recovered from SARS-Cov-2 infection: results from the OnCovid registry. 49
Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis 48
Hepatitis B virus and lymphomagenesis: novel insights into an occult relationship 47
GENDER-RELATED DISTRIBUTION OF THE INTERLEUKIN-1BETA AND INTERLEUKIN-1 RECEPTOR ANTAGONIST GENE POLYMORPHISMS IN PATIENTS WITH END-STAGE LIVER DISEASE 46
Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: The OnCovid Inflammatory Score 46
Time-Dependent COVID-19 Mortality in Patients with Cancer: An Updated Analysis of the OnCovid Registry 46
L’impatto del Long COVID è stato minore nella terza ondata della pandemia rispetto alla prima ondata in una popolazione italiana di 324 pazienti. 45
Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study 45
Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy 44
The Kings Score refines prognostic prediction in hepatocellular carcinoma: a novel application 43
The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma 42
INTERLEUKIN-6 POLYMORPHISMS AND GENDER: RELATIONSHIP WITH THE OCCURRENCE OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH END-STAGE LIVER DISEASE 41
Reliability and reproducibility of the edmondson grading of hepatocellular carcinoma using paired core biopsy and surgical resection specimens 41
Preliminary qualification of a novel, hypoxic-based radiologic signature for trans-arterial chemoembolization in hepatocellular carcinoma 41
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort 41
Determinants of long COVID among adults hospitalized for SARS-CoV-2 infection: A prospective cohort study 39
Assessing the impact of COVID-19 on liver cancer management (CERO-19) 39
Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer 39
Tissue biomarkers of prognostic significance in hepatocellular carcinoma. 38
Back from the brink: EGFR inhibition in gastroesophageal cancer 37
Advanced age influences the dynamic changes in circulating C-reactive protein following injury 37
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study 36
Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach 35
Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer 35
Antibiotic therapy and outcome from immune-checkpoint inhibitors 35
Artemisia: A divine dart against cancer? 34
Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis 34
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy 34
The systemic pro-inflammatory response: targeting the dangerous liaisonbetween COVID-19 and cancer 34
Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study 33
Phenotypic Characteristics of the Tumour Microenvironment in Primary and Secondary Hepatocellular Carcinoma 33
ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma 32
Antibiotic Treatment and Immune Checkpoint Inhibitor Therapy in Patients with Cancer - Reply 32
COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry 31
Antibiotic-induced Dysbiosis as a Putative Actionable Driver of Cancer Immunity in Renal Cell Carcinoma 30
An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trials 29
Alterations of choline phospholipid metabolism in endometrial cancer are caused by choline kinase alpha overexpression and a hyperactivated deacylation pathway 29
International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma 29
Applicability of Routine Targeted Next-generation Sequencing to Estimate Tumor Mutational Burden (TMB) in Patients Treated with Immune Checkpoint Inhibitor Therapy 29
Knowledge and attitudes of Italian medical oncologists and palliative care physicians toward medical use of cannabis in cancer care: a national survey 29
An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma 28
NASH limits anti-tumour surveillance in immunotherapy-treated HCC 28
A novel and validated prognostic index in hepatocellular carcinoma: The inflammation based index (IBI) 28
Acceleration of interstitial lung disease induced by raltitrexed 28
The albumin-bilirubin grade uncovers the prognostic relationship between hepatic reserve and immune dysfunction in HIV-associated hepatocellular carcinoma 28
Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy 28
A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: The prognostic nutritional index (PNI) 27
A Pilot Randomized, Placebo Controlled, Double Blind Phase I Trial of the Novel SIRT1 Activator SRT2104 in Elderly Volunteers 27
Combined PD-1/VEGFR Blockade: A New Era of Treatment for Hepatocellular Cancer 27
Biliary tract cancers: Molecular heterogeneity and new treatment options 27
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study 27
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer 26
Isogeneic comparison of primary and metastatic lung cancer identifies CX3CR1 as a molecular determinant of site-specific metastatic diffusion 26
Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: Implications for immunotherapy 26
Comparative efficacy of atezolizumab plus bevacizumab and other treatment options for patients with unresectable hepatocellular carcinoma: A network meta-analysis 26
Repurposed floxacins targeting RSK4 prevent chemoresistance and metastasis in lung and bladder cancer 26
T-cell mediated responses against alpha-foetoprotein in hepatocellular carcinoma: Relationship with hepatitis C virus infection, tumour phenotype and patients’ survival 26
Blood Epstein–Barr virus DNA does not predict outcome in advanced HIV-associated Hodgkin lymphoma 25
COVID-19 and Cancer: A Review of the Registry-Based Pandemic Response 25
Response to letter entitled: Re: Predictive ability of a drug-based score in advanced non-small cell lung cancer patients receiving first-line immunotherapy 25
An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: Correlation with tumour phenotype and survival outcomes 24
An unexpected cause of pulmonary cannonball lesion 24
A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors 24
Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma 23
Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association? 23
Evaluating the impact of COVID-19 on supportive care needs, psychological distress and quality of life in UK cancer survivors and their support network 23
PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects 23
Immunotherapies for hepatocellular carcinoma 22
Transcriptional analysis of multiple ovarian cancer cohorts reveals prognostic and immunomodulatory consequences of ERV expression 22
Capsaicin 8% patch for treprostinil subcutaneous infusion site pain in pulmonary hypertension patients 22
Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective 21
Inflammation as a validated prognostic determinant in carcinoma of unknown primary site 21
Immunohistochemical markers of the hypoxic response can identify malignancy in phaeochromocytomas and paragangliomas and optimize the detection of tumours with VHL germline mutations 21
Programmed cell death ligands expression in phaeochromocytomas and paragangliomas: Relationship with the hypoxic response, immune evasion and malignant behavior 21
Systemic Inflammatory Response Is a Prognostic Marker in HIV-Infected Patients with Hepatocellular Carcinoma 21
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index 21
Programmed death ligand 1 (PD-L1) expression influences the immune-tolerogenic microenvironment in antiretroviral therapy-refractory Kaposi's sarcoma: A pilot study 21
TAMing resistance to multi-targeted kinase inhibitors through Axl and Met inhibition 21
Immune-based therapies for hepatocellular carcinoma 21
Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study 21
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study 21
MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-a, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial 21
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice 21
CD24: A potential new marker in differentiating malignant mesothelioma from pulmonary adenocarcinoma 20
Developing an objective marker to optimize patient selection and predict survival benefit in early-phase cancer trials 20
Totale 3.515
Salva come PNG Salva come JPEG
Categoria #
all - tutte 51.888
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 51.888
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020165 0 0 0 0 0 0 56 21 32 29 26 1
2020/2021400 29 0 24 1 28 5 28 5 26 113 128 13
2021/2022799 27 2 174 71 46 6 24 21 68 63 126 171
2022/20231.810 217 43 77 6 51 106 43 79 1.132 5 27 24
2023/20241.084 136 46 82 33 209 14 222 15 4 39 56 228
2024/2025701 45 26 204 19 36 331 40 0 0 0 0 0
Totale 5.224